Barry, OppHub America Desk · · Source: yahoo-tickers-rotation
ResMed Q3 Revenue Rises 9% to $1.5B Amid Sleep Apnea Demand
If sustains its device revenue momentum across the Americas, traders watch for multiple expansion supported by institutional accumulation and recent analyst target revisions.
Based on reporting from yahoo-tickers-rotation.
ResMed Inc. (NYSE: RMD) posted fiscal 2026 revenue of $1.5 billion, up 9% year over year, driven by sustained demand for sleep devices, masks, and accessories. Despite competitive pressures and differing analyst expectations for future guidance, institutional positioning showed notable adjustments as market participants weigh segment growth against sector headwinds.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
ResMed·$RMD$RMDResMed
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/RMD. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
ResMed Inc. (NYSE: RMD) reported a 9% year-over-year increase in revenue to $1.5 billion for fiscal 2026, supported by strong demand across sleep devices, masks, and accessories. Growth was highlighted by a 6% increase in Americas device revenue and an 8% rise in total Americas Sleep and Breathing Health revenue, alongside a 10% gain in Americas masks and other revenue.
### Tape / Session Read Institutional interest in ResMed Inc. (NYSE: RMD) reflects broader health sector positioning. Recent institutional disclosures revealed that Arrowstreet Capital increased its stake by 151% to approximately $220.16 million, while another holder raised its position by 161% to about $177.14 million. Meanwhile, short interest sits at 9.06% of shares outstanding, pointing to active positioning as the company navigates competitive pressures.
### Why This Lane Matters For market participants tracking healthcare and medical device equities, ResMed's performance offers insight into consumer and clinical demand for sleep apnea solutions. Differing forecasts—such as revenue projections ranging between $5.75 billion and $5.85 billion compared to analyst expectations of $5.92 billion—highlight the tension between current device demand and broader sector expectations.
### Money Play If $RMD+WL sustains its device revenue momentum across the Americas, traders watch for multiple expansion supported by institutional accumulation. Analysts recently adjusted price targets, with one firm lifting its target to $262 from $244 while upgrading its rating from Sector Perform.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
If sustains its device revenue momentum across the Americas, traders wat
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: September 19, 2026 at 9:26 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
sleep apnea medical devices
A major medical device company reported higher sales because more people are buying sleep apnea machines and accessories. Investors care because big financial firms are buying more shares, even though some analysts have mixed expectations for future growth.
What changed
ResMed posted a 9% revenue increase to $1.5 billion, sparking heavy institutional accumulation alongside ongoing debate over future guidance.
Who wins / who loses
Sleep apnea device makers and suppliers benefit from steady clinical demand, while competitors and heavily shorted peers face pressure if top-line momentum holds.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor, Active trader
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $RMDWatch — track, don’t rush
The main company in the news is growing sales, and big investment funds are buying in, but we want to see if future sales match their hopes.
View $RMD chart → · End-of-day delayed data
Peer
- $MDTWatch — track, don’t rush
Other big medical supply companies often move up or down when the whole healthcare sector gets attention.
View $MDT chart → · End-of-day delayed data
Second-order
- $ISRGWatch — track, don’t rush
Other high-end medical equipment makers reflect how much hospitals and clinics are spending.
View $ISRG chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should skip options here and stick to regular shares or broad funds if they want to participate.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Researching durable medical equipment distributors and suppliers operating in the respiratory and sleep health space.
What would break this thesis
- A significant slowdown in Americas device revenue growth or lowered forward guidance below analyst consensus.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-rotation.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).